Literature DB >> 17559204

Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.

Daniel R McMasters1, Rhonda A Torres, Susan J Crathern, Deborah L Dooney, Robert B Nachbar, Robert P Sheridan, Kenneth R Korzekwa.   

Abstract

The affinities of a diverse set of 500 drug-like molecules to cytochrome P450 isoforms 2C9 and 2D6 were measured using recombinant expressed enzyme. The dose-response curve of each compound was fitted with a series of equations representing typical or various types of atypical kinetics. Atypical kinetics was identified where the Akaike Information Criterion, plus other criteria, suggested the kinetics was more complex than expected for a Michaelis-Menten model. Approximately 20% of the compounds were excluded due to poor solubility, and approximately 15% were excluded due to fluorescence interference. Of the remaining compounds, roughly half were observed to bind with an affinity of 200 microM or lower for each of the two isoforms. Atypical kinetics was observed in 18% of the compounds that bind to cytochrome 2C9, but less than 2% for 2D6. The resulting collection of competitive inhibitors and inactive compounds were analyzed for trends in binding affinity. For CYP2D6, a clear relationship between polar surface area and charge was observed, with the most potent inhibitors having a formal positive charge and a low percent polar surface area. For CYP2C9, no clear trend between activity and physicochemical properties could be seen for the group as a whole; however, certain classes of compounds have altered frequencies of activity and atypical kinetics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17559204      PMCID: PMC2547349          DOI: 10.1021/jm0700060

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

1.  Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro.

Authors:  K Venkatakrishnan; L L von Moltke; R S Obach; D J Greenblatt
Journal:  J Pharmacol Exp Ther       Date:  2000-05       Impact factor: 4.030

2.  Identification and prediction of promiscuous aggregating inhibitors among known drugs.

Authors:  James Seidler; Susan L McGovern; Thompson N Doman; Brian K Shoichet
Journal:  J Med Chem       Date:  2003-10-09       Impact factor: 7.446

3.  Generation and evaluation of a CYP2C9 heteroactivation pharmacophore.

Authors:  Ann-Charlotte Egnell; Cecilia Eriksson; Nan Albertson; Brian Houston; Scott Boyer
Journal:  J Pharmacol Exp Ther       Date:  2003-10-13       Impact factor: 4.030

4.  Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.

Authors:  Jeannine M Margolis; R Scott Obach
Journal:  Drug Metab Dispos       Date:  2003-05       Impact factor: 3.922

5.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism.

Authors:  K E Kenworthy; S E Clarke; J Andrews; J B Houston
Journal:  Drug Metab Dispos       Date:  2001-12       Impact factor: 3.922

6.  In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine.

Authors:  Ann-Charlotte Egnell; Brian Houston; Scott Boyer
Journal:  J Pharmacol Exp Ther       Date:  2003-01-24       Impact factor: 4.030

7.  Crystal structure of human cytochrome P450 2C9 with bound warfarin.

Authors:  Pamela A Williams; Jose Cosme; Alison Ward; Hayley C Angove; Dijana Matak Vinković; Harren Jhoti
Journal:  Nature       Date:  2003-07-13       Impact factor: 49.962

8.  Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations.

Authors:  J Matthew Hutzler; Larry C Wienkers; Jan L Wahlstrom; Timothy J Carlson; Timothy S Tracy
Journal:  Arch Biochem Biophys       Date:  2003-02-01       Impact factor: 4.013

9.  Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.

Authors:  Aleksandra Galetin; Stephen E Clarke; J Brian Houston
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

10.  Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9.

Authors:  Leslie J Dickmann; Charles W Locuson; Jeffrey P Jones; Allan E Rettie
Journal:  Mol Pharmacol       Date:  2004-04       Impact factor: 4.436

View more
  10 in total

1.  Evaluation of descriptors and classification schemes to predict cytochrome substrates in terms of chemical information.

Authors:  John H Block; Douglas R Henry
Journal:  J Comput Aided Mol Des       Date:  2008-01-23       Impact factor: 3.686

2.  Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.

Authors:  Yaroslava Karpova; Chao Wu; Ali Divan; Mark E McDonnell; Elizabeth Hewlett; Peter Makhov; John Gordon; Min Ye; Allen B Reitz; Wayne E Childers; Tomasz Skorski; Vladimir Kolenko; Alexei V Tulin
Journal:  Biochem Pharmacol       Date:  2019-03-15       Impact factor: 5.858

3.  A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations.

Authors:  Swati Nagar; Jeffrey P Jones; Ken Korzekwa
Journal:  Drug Metab Dispos       Date:  2014-06-17       Impact factor: 3.922

4.  A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. Application to experimental data.

Authors:  Ken Korzekwa; Donald Tweedie; Upendra A Argikar; Andrea Whitcher-Johnstone; Leslie Bell; Shari Bickford; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2014-06-17       Impact factor: 3.922

5.  Enzyme Kinetics of Oxidative Metabolism-Cytochromes P450.

Authors:  Ken Korzekwa
Journal:  Methods Mol Biol       Date:  2021

6.  Impact of Lipid Partitioning on the Design, Analysis, and Interpretation of Microsomal Time-Dependent Inactivation.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2019-05-01       Impact factor: 3.922

7.  SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases.

Authors:  Abdelsattar M Omar; Maan T Khayat; Farid Ahmed; Yosra A Muhammad; Azizah M Malebari; Sara M Ibrahim; Mohammad I Khan; Dhaval K Shah; Wayne E Childers; Moustafa E El-Araby
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

8.  MC-100093, a Novel β-Lactam Glutamate Transporter-1 Enhancer Devoid of Antimicrobial Properties, Attenuates Cocaine Relapse in Rats.

Authors:  Lori A Knackstedt; Lizhen Wu; Jeffrey Rothstein; Svetlana Vidensky; John Gordon; Mercy Ramanjulu; Paul Dunman; Benjamin Blass; Wayne Childers; Magid Abou-Gharbia
Journal:  J Pharmacol Exp Ther       Date:  2021-05-13       Impact factor: 4.402

9.  Microsecond MD simulations of human CYP2D6 wild-type and five allelic variants reveal mechanistic insights on the function.

Authors:  Charleen G Don; Martin Smieško
Journal:  PLoS One       Date:  2018-08-22       Impact factor: 3.240

10.  Insights on Cancer Cell Inhibition, Subcellular Activities, and Kinase Profile of Phenylacetamides Pending 1H-Imidazol-5-One Variants.

Authors:  Maan T Khayat; Abdelsattar M Omar; Farid Ahmed; Mohammad I Khan; Sara M Ibrahim; Yosra A Muhammad; Azizah M Malebari; Thikryat Neamatallah; Moustafa E El-Araby
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.